[go: up one dir, main page]

ME03316B - Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora - Google Patents

Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora

Info

Publication number
ME03316B
ME03316B MEP-2019-19A MEP201919A ME03316B ME 03316 B ME03316 B ME 03316B ME P201919 A MEP201919 A ME P201919A ME 03316 B ME03316 B ME 03316B
Authority
ME
Montenegro
Prior art keywords
као
modulatorsokorтikoidnog
benzoksazinon
receptora
starches
Prior art date
Application number
MEP-2019-19A
Other languages
German (de)
English (en)
French (fr)
Inventor
Gavin O'mahony
Michael Kossenjans
Karl Edman
Johan Kajanus
Carl Anders Hogner
Philip Cornwall
Andrew Turner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME03316B publication Critical patent/ME03316B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MEP-2019-19A 2014-06-30 2015-06-26 Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora ME03316B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
EP15736015.7A EP3160948B1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
ME03316B true ME03316B (me) 2019-10-20

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-19A ME03316B (me) 2014-06-30 2015-06-26 Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora

Country Status (26)

Country Link
US (2) US10017502B2 (me)
EP (1) EP3160948B1 (me)
JP (1) JP6368383B2 (me)
KR (1) KR102012222B1 (me)
CN (1) CN106536491B (me)
AR (1) AR101036A1 (me)
AU (1) AU2015282450C1 (me)
CA (1) CA2953655C (me)
CY (1) CY1121596T1 (me)
DK (1) DK3160948T3 (me)
EA (1) EA029518B1 (me)
ES (1) ES2707726T3 (me)
HR (1) HRP20190147T1 (me)
HU (1) HUE042370T2 (me)
LT (1) LT3160948T (me)
ME (1) ME03316B (me)
MX (1) MX367404B (me)
PL (1) PL3160948T3 (me)
PT (1) PT3160948T (me)
RS (1) RS58274B1 (me)
SI (1) SI3160948T1 (me)
SM (1) SMT201900039T1 (me)
TR (1) TR201900659T4 (me)
TW (1) TWI677498B (me)
UY (1) UY36195A (me)
WO (1) WO2016001631A1 (me)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3160948T3 (pl) * 2014-06-30 2019-04-30 Astrazeneca Ab Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych
CA3105626A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
JOP20200098A1 (ar) 2019-08-30 2021-02-28 Astrazeneca Ab طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
AU2022292685A1 (en) * 2021-06-15 2024-01-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzoxazinone derivatives
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
WO2024047574A1 (en) 2022-09-01 2024-03-07 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
WO2024125591A1 (zh) * 2022-12-15 2024-06-20 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528335A (ja) * 2001-04-23 2004-09-16 アストラゼネカ アクチボラグ 血管新生の治療に使用のベンゾオキサジノン誘導体
CA2510851A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
MX2007000449A (es) * 2004-07-14 2007-03-28 Ligand Pharm Inc Compuestos moduladores de receptor intracelular y metodos.
KR20070046150A (ko) * 2004-07-28 2007-05-02 아이알엠 엘엘씨 스테로이드 호르몬 핵 수용체의 조절제로서의 화합물 및조성물
JP2009523701A (ja) 2005-12-28 2009-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
SI2089367T1 (sl) 2006-10-31 2012-02-29 Pfizer Prod Inc Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
JP2010522168A (ja) 2007-03-23 2010-07-01 メルク・シャープ・エンド・ドーム・コーポレイション 鉱質コルチコイドレセプターモジュレータ
JP5363312B2 (ja) 2007-04-09 2013-12-11 第一三共株式会社 ピロール誘導体のアトロプ異性体
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
UY31905A (es) * 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
EA019179B1 (ru) 2009-03-12 2014-01-30 Эли Лилли Энд Компани Антагонист минералокортикоидного рецептора и способы его применения
JP2012523405A (ja) 2009-04-10 2012-10-04 ファイザー・インク 4,5−ジヒドロ−1h−ピラゾール化合物およびその薬学的使用
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
US8979337B2 (en) 2010-05-11 2015-03-17 Koninklijke Philips N.V. Lighting module
JPWO2012008435A1 (ja) 2010-07-13 2013-09-09 大日本住友製薬株式会社 ビアリールアミド誘導体またはその薬理学的に許容される塩
JP2013542255A (ja) 2010-11-10 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素
PL3160948T3 (pl) * 2014-06-30 2019-04-30 Astrazeneca Ab Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych

Also Published As

Publication number Publication date
KR102012222B1 (ko) 2019-10-21
CN106536491A (zh) 2017-03-22
MX367404B (es) 2019-08-20
ES2707726T3 (es) 2019-04-04
CA2953655A1 (en) 2016-01-07
MX2017000183A (es) 2017-04-25
CY1121596T1 (el) 2020-05-29
AU2015282450C1 (en) 2018-09-20
RS58274B1 (sr) 2019-03-29
PT3160948T (pt) 2019-02-01
US20170217945A1 (en) 2017-08-03
AU2015282450A1 (en) 2017-02-02
EP3160948B1 (en) 2018-10-24
EA201790046A1 (ru) 2017-08-31
CA2953655C (en) 2020-05-12
SMT201900039T1 (it) 2019-02-28
LT3160948T (lt) 2019-02-11
TWI677498B (zh) 2019-11-21
EA029518B1 (ru) 2018-04-30
TW201613909A (en) 2016-04-16
JP6368383B2 (ja) 2018-08-01
TR201900659T4 (tr) 2019-02-21
DK3160948T3 (en) 2019-02-18
KR20170021883A (ko) 2017-02-28
PL3160948T3 (pl) 2019-04-30
US9394291B2 (en) 2016-07-19
CN106536491B (zh) 2018-12-18
US10017502B2 (en) 2018-07-10
US20150376170A1 (en) 2015-12-31
SI3160948T1 (sl) 2020-06-30
UY36195A (es) 2016-01-08
AR101036A1 (es) 2016-11-16
HUE042370T2 (hu) 2019-06-28
JP2017522300A (ja) 2017-08-10
EP3160948A1 (en) 2017-05-03
HRP20190147T1 (hr) 2019-03-22
AU2015282450B2 (en) 2018-05-10
WO2016001631A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da) Karadgang
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
DK3174483T3 (da) Hyporørkonstruktion
EP3230438C0 (en) N-GLYCOSYLATION
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
MA41015A (fr) Hydrocyclone anti-boudinage
ME03316B (me) Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
DE112015001664A5 (de) Betätigungsaktuator
DK3183340T3 (da) Termolabile exonukleaser
DK3110439T3 (da) Pcsk9-vacciner
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DK3091875T3 (da) Vipbar taburet
DE202014005655U8 (de) llluminationsvorrichtung
DE112015005055A5 (de) Gargerätevorrichtung
DK3191825T3 (da) Kreatininbiosensor
ES1137381Y (es) Trompo
ES1136185Y (es) Huevera